CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

NCT02286726 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]